News

Joint Net4CGD / CELL-PID Annual Meeting 2014

February 25 @ 09:00 - February 26 @ 12:00

Grand Hôtel des Iles Borromées, Corso Umberto I, 67 Stresa - Italy

Net4CGD and CELL-PID are holding their first joint meeting in Stresa, Italy. The agenda for this meeting will have a strong scientific focus, including joint sessions and many opportunities for interactions between scientists from both groups and within each consortium.

Marking their first Annual Meeting, this event will give the Net4CGD consortium the opportunity to look back on the scientific progress and breakthroughs achieved over the first year of the work programme.

Contact : Dr Elodie Noël (Email address: This email address is being protected from spambots. You need JavaScript enabled to view it. )

Net4CGD network, sponsor of the ESGCT and SETGyC Collaborative Congress

The net4CGD network is a proud sponsor of the ESGCT and SETGyC Collaborative Congress,
Madrid from October 25 to 28, 2013.   

The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy, and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.

The XXIInd annual ESGCT Congress with the NVGCT will take place in The Hague 23 to 26 October 2014.
For more information go to http://www.esgct.eu

Public Presentation of the Net4CGD consortium

April 30, 2013 - 14h30

Plenary talk by Pr. Reinhard Seger University of Zurich, Switzerland.
“From bone marrow transplantation to gene therapy : Specific challenges and therapeutic progress in chronic granulomatous disease (CGD)”
 
Address of the venue : Genocentre, 1 rue de l’Internationale, 91002 Evry, France (www.genocentre.fr).
Contact : This email address is being protected from spambots. You need JavaScript enabled to view it.

Gene TherapyLogoPRGenethon-AFMTelethon

Press Release - Evry, February 5, 2013

Genethon receives approval from the UK medicine regulatory agency to start a new clinical trial for an inherited immune deficiency : chronic granulomatous disease.

Continue Reading